Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Profound Medical ( (TSE:PRN) ) just unveiled an update.
Profound Medical will unveil the first clinical outcomes from its Level 1 post-market CAPTAIN trial, which compares the safety and efficacy of the TULSA Procedure with robotic radical prostatectomy in localized prostate cancer, at the European Association of Urology 2026 Congress in London on March 13. The data will be presented by leading urologist Dr. Laurence Klotz, after which the company will issue a summary release and host an investor webinar to review the clinical findings and discuss the commercial implications and steps toward potential inclusion of TULSA in prostate cancer treatment guidelines.
In addition, Profound’s management will hold a series of one-on-one investor meetings at the 38th Annual Roth Conference in Dana Point, California, from March 22 to 24, underscoring the company’s efforts to deepen engagement with the investment community. Together, these events highlight Profound’s push to validate TULSA clinically against surgical standards and to leverage emerging data to strengthen its positioning in the prostate cancer treatment market and broaden investor awareness.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$7.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (downtrend across key moving averages with negative momentum). The earnings call adds support via credible growth/profitability targets, reimbursement and pipeline tailwinds, while valuation remains constrained by ongoing losses and no stated dividend.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO platform delivers real-time MRI-guided prostate treatments aimed at minimizing side effects, while its Sonalleve system offers non-surgical MRI-guided therapies for bone metastases, certain tumors, and gynecologic conditions, with regulatory approvals across major global markets.
Average Trading Volume: 18,418
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$257M
See more insights into PRN stock on TipRanks’ Stock Analysis page.